Skip to main content
Premium Trial:

Request an Annual Quote

Mara Aspinall

Mara Aspinall was named executive chairman of the Lifeprint Group's board of directors. Aspinall currently is CEO of the consulting firm Health Catalysts. She was previously the president and CEO of Roche's Ventana Medical Systems. She also spent more than a decade at Genzyme, where she held various leadership roles, including president of Genzyme Genetics and Genzyme Pharmaceuticals.

The appointment was announced by GenePeeks, a firm held by Lifeprint, which uses next-generation sequencing to help parents assess the risk of inherited diseases for their future children. 

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.